...
首页> 外文期刊>Oral oncology >Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
【24h】

Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.

机译:光动力疗法联合单L-天冬氨酰二氢卟酚e6(NPe6)在口腔鳞状细胞癌中表达血管内皮生长因子。

获取原文
获取原文并翻译 | 示例
           

摘要

Photodynamic therapy (PDT) is a method for treating pre-cancerous and cancerous lesions of the skin, bladder and oral cavity. However, tumour recurrence after PDT remains problematic despite good initial response. Some studies have shown that PDT induces vascular endothelial growth factor (VEGF) expression in human oral squamous cell carcinoma and other organs. However, little is known about VEGF expression applied to PDT in human carcinoma cell lines. No studies have been conducted of PDT using Npe6 (Npe6-mediated PDT), a second-generation photosensitizer, in the human oral carcinoma cell line, HSC-3 cells. We investigated the expression of VEGF, c-jun and c-fos proto-oncogenes in HSC-3 cells in response to Npe6-mediated PDT. We also addressed the possibility that oxidative damage induced by PDT could lead to an angiogenic response, via VEGF expression. Reverse transcription polymerase chain reaction (RT-PCR) analysis revealed that Npe6-mediated PDT induced the expression of mRNAs for VEGF, c-jun and c-fos in time- and concentration-dependent manners. Desferrioxamine (DFX), an iron chelator, induced VEGF expression, but the expression pattern was different to that of Npe6-mediated PDT. The expression mRNAs for VEGF, c-jun and c-fos induced by Npe6-mediated PDT were inhibited by SB203580, p38 MAPK inhibitors, and the expression of VEGF mRNA was inhibited by cycloheximide (CHX), a protein synthesis inhibitor. The c-jun mRNA expression was inhibited, whereas the c-fos mRNA expression was enhanced by N-acetyl-L-cysteine (NAC), a free radical scavenger. We conclude that Npe6-mediated PDT induces the expression of VEGF, c-jun and c-fos in human oral carcinoma cell line, HSC-3 cell, and at least partly, through the activation of p38 MAPK.
机译:光动力疗法(PDT)是一种治疗皮肤,膀胱和口腔癌前期和癌前病变的方法。然而,尽管初期反应良好,但PDT后的肿瘤复发仍然存在问题。一些研究表明,PDT在人口腔鳞状细胞癌和其他器官中诱导血管内皮生长因子(VEGF)的表达。然而,关于在人癌细胞系中应用于PDT的VEGF表达知之甚少。还没有在人类口腔癌细胞系HSC-3细胞中使用第二代光敏剂Npe6(Npe6介导的PDT)对PDT进行研究。我们调查了Npe6介导的PDT在HSC-3细胞中VEGF,c-jun和c-fos原癌基因的表达。我们还解决了PDT诱导的氧化损伤可能通过VEGF表达导致血管生成反应的可能性。逆转录聚合酶链反应(RT-PCR)分析表明,Npe6介导的PDT以时间和浓度依赖性方式诱导VEGF,c-jun和c-fos的mRNA表达。铁螯合剂去铁胺(DFX)诱导VEGF表达,但其表达模式与Npe6介导的PDT不同。 Npe6介导的PDT诱导的VEGF,c-jun和c-fos的mRNA表达被SB203580,p38 MAPK抑制剂抑制,而VEGF mRNA的表达被蛋白质合成抑制剂cycloheximide(CHX)抑制。 c-jun mRNA表达受到抑制,而c-fos mRNA表达则被自由基清除剂N-乙酰基-L-半胱氨酸(NAC)增强。我们得出的结论是,Npe6介导的PDT诱导人口腔癌细胞系HSC-3细胞中VEGF,c-jun和c-fos的表达,并且至少部分地通过p38 MAPK的激活来诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号